Últimas noticias sobre Ferrovial (NASDAQ:FER) Bolsa

Ferrovial SE is a Spanish industrial company. The company organizes itself into four segments: Toll Roads, Airports, Construction, and Energy. The Toll Roads segment develops and operates toll roads globally. The Airports segment includes the Development, financing and operation of airports. The Construction segment Designs and executes all public and private works, including most notably the construction of public infrastructures. The Energy segment focuses on innovative solutions for promoting, constructing and operating energy generation and transmission infrastructures.

Banco Santander

BBVA

Las recompras de acciones impulsan a Santander, BBVA y CaixaBank en bolsa, fortaleciendo la confianza en el sector bancario.

Santander (SAN), BBVA (BBVA) y CaixaBank (CABK) disparan su valor con recompras de acciones

Autopista

El fuerte crecimiento financiero de Ferrovial y su modelo de autopistas de peaje la posicionan como una inversión clave en el mercado.

Acciones de Ferrovial (FER) reciben respaldo de Deutsche Bank y podrían ganar un 40%

Ibex

Las bolsas europeas operan mixtas con el Ibex 35 prácticamente plano. Inversores atentos a la Fed y su decisión sobre tipos de interés.

Mercados europeos mixtos: Ibex 35 estable y la Fed en el foco

Ferrovial SE

Fifth Era Acquisition Corp I - Class A Ordinary Shares

Fifth Era Acquisition Corp I

Fifth Era Acquisition Corp I - Rights

Ferguson Enterprises Inc

Fearless Films Inc

Fernhill Corp

WIIM

PRTG

Portage Biotech shares are trading higher after the company reported confirmatory preclinical efficacy data for PORT-7.

Barrington Research analyst Vincent Colicchio maintains Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) with a Outperform and maintains $17 price target.

News

Price Target

Analyst Ratings

ASUR

Barrington Research Maintains Outperform on Asure Software, Maintains $17 Price Target

Biotech

Health Care

General

VRTX

The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion For Vertex Pharmaceuticals' Alyftrek (Deutivacaftor/Tezacaftor/Vanzacaftor) For Cystic Fibrosis Patients Aged 6 Years And Older Who Have At Least One Non-class I Mutation In The Cystic Fibrosis Transmembrane Conductance Regulator Gene.

Keybanc analyst Todd Thomas initiates coverage on Smartstop Self Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMA#NYSE">SMA</a>) with a Overweight rating and announces Price Target of $38.

Initiation

Keybanc Initiates Coverage On Smartstop Self Storage with Overweight Rating, Announces Price Target of $38

Rosenblatt analyst Barton Crockett maintains Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) with a Neutral and maintains $36 price target.

CMCSA

Rosenblatt Maintains Neutral on Comcast, Maintains $36 Price Target

TD Securities analyst Andrew Charles maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Hold and lowers the price target from $40 to $31.

JACK

TD Securities Maintains Hold on Jack In The Box, Lowers Price Target to $31

British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>, BCTXW))))("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is presenting positive data from its Phase 2 study of lead product candidate, Bria-IMT&#x2122;, in metastatic breast cancer, and from its preclinical Bria-OTS+ platform at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. In addition, Phase 3 early biomarker data will be presented as a late breaking abstract.

BCTX

BriaCell Showcases Phase 2 Results for Breast Cancer Therapy at Major Cancer Conference

CORRECTION: V2X Ticker Is 'VVX'

Ascendiant Capital analyst Edward Woo maintains Duos Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOT#NASDAQ">DUOT</a>) with a Buy and raises the price target from $7.5 to $9.

DUOT

Ascendiant Capital Maintains Buy on Duos Technologies Group, Raises Price Target to $9

Alterity Therapeutics ((ASX: ATH, NASDAQ:<a href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer presented the ATH434-201 Phase 2 clinical trial results at the annual MSA Research Symposium hosted by University College London, Institute of Neurology in partnership with the MSA Trust of the U.K.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Alterity Therapeutics Presents Phase 2 Results for Neurodegenerative Disease Treatment

D. Boral Capital analyst Jason Kolbert initiates coverage on Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) with a Buy rating and announces Price Target of $10.

CODX

D. Boral Capital Initiates Coverage On Co-Diagnostics with Buy Rating, Announces Price Target of $10

In the <a href="https://www.benzinga.com/25/04/45026616/trumps-trade-war-causes-sharp-decline-in-us-imports-from-china">changing landscape of global trade</a>, Kansas farmers are setting their sights on an old grain with a new vision. Sorghum, long regarded mainly as livestock feed, is being rebranded as the next superfood as growers race to acquire new buyers.
What Happened: China was once the top buyer of Sorghum, but it cancelled major purchases in January in anticipation of tariffs, according to the Wall Street Journal. As a result, storage facilities in Kansas are overflowing.
Speaking <a href="https://www.wsj.com/business/move-over-quinoa-theres-a-new-it-crop-in-town-7e371e42?mod=business_lead_pos2">to</a> the WSJ, Kim Barnes, CFO of Pawnee County Cooperative, said "I just kept turning over rocks and boulders until I found a place to go with it." He sold his stock to ethanol plants and feed businesses, incurring a loss.
Kansas produces most of the country's sorghum, but only a small portion is used for food. Promoters of the grain hope to change that. "We do see sorghum as kind of that ‘it' crop for domestic food," said Adam York, head of Kansas Sorghum Producers.
See Also: <a href="https://www.benzinga.com/25/04/45033064/16-million-chinese-jobs-under-threat-amid-escalating-us-china-trade-war-predicts-goldman-sachs">16 Million Jobs At Risk In China As US Tariffs Hammer Manufacturing And Retail Sectors, Goldman Sachs Warns</a>
Why It Matters: Despite its benefits, sorghum has a long way to go, because many see it primary as cattle feed. "Because so many of us were raised on farms, there is that barrier," said dietitian Missy Schrader to the WSJ. 
Despite challenges, chef George Duran is optimistic. "If we could just market it as maybe, like, ‘The Miracle Grain' or something, I think it can really go pretty far," he said.
Sorghum is the latest addition to the list of grains that have been touted as superfoods of the future. Last year, Microsoft co-founder Bill Gates spotlighted Fonio, a lesser-known African grain, as a game-changer that can serve as a vital staple in its native regions and also emerge as a potential solution to <a href="https://www.benzinga.com/news/24/04/38508127/bill-gates-says-americans-are-obsessed-with-wheat-and-corn-but-this-lost-grain-from-africa-is-the-fu">global food sustainability challenges</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/45031287/us-companies-earn-6x-more-in-china-than-they-export-heres-why-blowing-up-global-trade-would-be-economic-suicidesays-leading-fund-manager">S&amp;P 500 Companies Earn 6x More In China Than US Exports: Hedge Fund Manager Says Trade War With Beijing Level Of Stupidity That Has &#8216;No Precedent&#8217;</a></li>
</ul>
Image Via Shutterstock

Kansas Farmers Push Sorghum As The Next Superfood Amid Trade War Strains And Surging Stockpiles

HALO

Halozyme Announces argenx Received A Positive CHMP Opinion Recommending EC Approval Of VYVGART 1000mg Developed With VYVGART 1000mg For Chronic Inflammatory Demyelinating Polyneuropathy

V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) Inc., has been awarded a $103 million contract by the U.S. Navy for Contractor Logistics Support (CLS) maintenance of C-26 aircraft, reinforcing V2X's role as the best-value provider for this critical mission.
Under this contract, V2X will continue providing comprehensive CLS support, including aircraft engineering, upgrades maintenance and modifications.
"This award highlights the Navy's continued confidence in V2X's proven ability to deliver mission-capable aircraft with exceptional performance," said Jeremy C. Wensinger, President and Chief Executive Officer at V2X. "With a longstanding history of supporting Navy aviation, this contract reaffirms our commitment to providing mission-ready aircraft that enhance operational readiness worldwide."
"With readiness rates north of 90%, V2X consistently delivers mission-capable aircraft while managing all aspects of maintenance, personnel, and equipment," said Vinny Caputo, Senior Vice President of Aerospace Systems at V2X. "A key&nbsp;differentiator in V2X's offering is our numerous FAA Part 145 repair stations, which are readiness multipliers," Caputo added.&nbsp;
Work for this firm-fixed-price contract is expected to begin in June 2025, supporting eight C-26A/D aircraft stationed at four main operating bases, including one U.S. location and three international sites.

Contracts

V2X Awarded $103M U.S. Navy Contract For C-26 Support

royalty payments on future troriluzole product net sales
<ul>
<li>$250 million to be funded at closing</li>
<li>$150 million available at the Company's option upon the achievement of regulatory milestones related to troriluzole</li>
<li>Up to $200 million at the mutual agreement of the parties for permitted strategic acquisitions and related costs and expenses</li>
</ul>

BHVN

Biohaven Announces $600M Non-Dilutive Funding Agreement With Oberland Capital To Advance Rare Disease Portfolio

All-new Vanquish Autonomous is designed to improve productivity and profitabilityWAUKESHA, Wis., April 28, 2025 /PRNewswire/ -- Mean Green, a leading battery-powered, commercial-grade turf care manufacturer and a Generac
All-new Vanquish Autonomous is designed to improve productivity and profitability
WAUKESHA, Wis., April 28, 2025 /PRNewswire/ -- Mean Green, a leading battery-powered, commercial-grade turf care manufacturer and a Generac Power Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) company, today announced the expansion of its commercial-grade electric mower lineup with its all-new Vanquish Autonomous.

GNRC

Mean Green Expands Commercial-Grade Electric Mower Lineup With Vanquish Autonomous

D. Boral Capital analyst Jason Kolbert maintains UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) with a Buy and maintains $25 price target.

URGN

D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target

Guardforce AI Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFAI#NASDAQ">GFAI</a>) reported quarterly losses of $(0.53) per share. This is a 88.3 percent increase over losses of $(4.53) per share from the same period last year. The company reported $36.35 million in sales this quarter. This is a 0.18 percent increase over sales of $36.28 million the same period last year.

Earnings

GFAI

Guardforce AI Co FY EPS $(0.53) Up From $(4.53) YoY, Sales $36.35M Up From $36.28M YoY

HSBC analyst Rajesh Kumar downgrades Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) from Buy to Reduce and lowers the price target from $1150 to $700.

Downgrades

HSBC Downgrades Eli Lilly to Reduce, Lowers Price Target to $700

OPRA

Opera shares are trading higher after the company announced better-than-expected Q1 financial results and raised its FY25 sales guidance above estimates. Also, the company issued Q2 sales guidance with its midpoint above estimates.

Comments

Ferrovial

Noticias

Últimas noticias sobre Ferrovial (NASDAQ:FER) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL